In 2015, the approval of flibanserin opened a debate about diagnosis and treatment of female sexual dysfunction. Designing clinical trials with suitable end points is difficult, but some studies indicate correlations between hormone levels and low desire. New research demonstrates opportunities for a better understanding of this multifaceted condition.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel
Supportive Care in Cancer Open Access 22 January 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Stahl, S. M. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 20, 1–6 (2015).
Thorp, J. Jr, Palacios, S., Symons, J., Simon, J. & Barbour, K. Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin. BJOG 121, 1328–1331 (2014).
Pyke, R. E. & Clayton, A. H. Psychological treatment trials for hypoactive sexual desire disorder: a sexual medicine critique and perspective. J. Sex. Med. 12, 2451–2458 (2015).
Sungur, M. Z. & Gündüz, A. A comparison of DSM-IV-TR and DSM-5 definitions for sexual dysfunctions: critiques and challenges. J. Sex. Med. 11, 364–373 (2014).
Sarin, S., Amsel, R. & Binik, Y. M. How hot is he? A psychophysiological and psychosocial examination of the arousal patterns of sexually functional and dysfunctional men. J. Sex. Med. 11, 1725–1740 (2014).
Portman, D. J., Edelson, J., Jordan, R., Clayton, A. & Krychman, M. L. Bremelanotide for hypoactive sexual desire disorder: analyses from a phase 2B dose-ranging study. Obstet. Gynecol. 123, 31S (2014).
Wierman, M. E. et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3489–3510 (2014).
Cunningham, G. R. et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J. Clin. Endocrinol. Metab. 100, 1146–1155 (2015).
Wåhlin-Jacobsen, S. et al. Is there a correlation between androgens and sexual desire in women? J. Sex. Med. 12, 358–373 (2015).
Randolph, J. F. Jr, Zheng, H., Avis, N. E., Greendale, G. A. & Harlow, S. D. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J. Clin. Endocrinol. Metab. 100, 258–266 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.E.N. had financial relationships (lecturer, member of advisory boards and/or consultant) with Bayer HealthCare, Boehringer Ingelheim, Ely Lilly, Endoceutics, Gedeon Richter, HRA Pharma, Merck Sharpe & Dohme, Novo Nordisk, Pfizer, Procter & Gamble, Shionogi Limited and TEVA Women's Health. F.A. declares no conflicts of interest.
Related links
Rights and permissions
About this article
Cite this article
Nappi, R., Albani, F. Recovering sex drive in women — progress and opportunities. Nat Rev Urol 13, 67–68 (2016). https://doi.org/10.1038/nrurol.2015.314
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.314
This article is cited by
-
Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel
Supportive Care in Cancer (2020)
-
Female sexual dysfunction: a call to arms for collaboration to understand the sexological elephant
Nature Reviews Urology (2016)